Aardvark Therapeutics, Inc.

AARD Nasdaq SEC CIK 1774857
Follow Aardvark Therapeutics Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $0
Net income −$19.2M −17.6% vs same quarter last year
EPS, diluted −$0.88 −17.3% vs same quarter last year
Operating cash flow −$13.5M +16.1% vs same quarter last year
Revenue by quarter
$0
$0
$0
$0
$0
$0
$0
Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing